SEGMENT REPORTING

9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

SEGMENT REPORTING

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):

	Core Companion Animal Health				Other Vaccines, Pharmaceuticals and Products	Total
Nine Months Ended September 30, 2012:
Total  revenue	$	45,811		$	8,541	$	54,352
Operating income (loss)		883			555		1,438
Interest expense		68			20		88
Total assets		51,194			11,784		62,978
Net assets		39,286			9,085		48,371
Capital expenditures		429			476		905
Depreciation and amortization		622			649		1,271
Nine Months Ended September 30, 2013:
Total  revenue	$	46,015		$	8,820	$	54,835
Operating income (loss)		(4,565	)		380		(4,185	)
Interest expense		208			21		229
Total assets		78,419			12,014		90,433
Net assets		37,217			9,251		46,468
Capital expenditures		466			804		1,270
Depreciation and amortization		1,113			602		1,715

	Core Companion Animal Health				Other Vaccines, Pharmaceuticals and Products	Total
Three Months Ended September 30, 2012:
Total revenue	$	13,530		$	3,376	$	16,906
Operating income (loss)		(126	)		99		(27	)
Interest expense		21			8		29
Total assets		51,194			11,784		62,978
Net assets		39,286			9,085		48,371
Capital expenditures		194			169		363
Depreciation and amortization		213			197		410
Three Months Ended September 30, 2013:
Total revenue	$	14,515		$	3,080	$	17,595
Operating income (loss)		(374	)		449		75
Interest expense		80			2		82
Total assets		78,419			12,014		90,433
Net assets		37,217			9,251		46,468
Capital expenditures		105			431		536
Depreciation and amortization		417			209		626